MPA (n=49) | No MPA (n=1928) | Age-sex adjusted | PSOW adjusted * | |||
Effect size (95% CI) | P value | Effect size (95% CI) | P value | |||
Severity | <0.001 | 0.94 | ||||
Mild | 26 (53.1) | 1306 (67.7) | 1.00 (ref.) | – | 1.00 (ref.) | – |
Moderate | 14 (28.6) | 408 (21.2) | 3.57 (1.76 to 7.21)† | <0.001 | 1.18 (0.40 to 3.45) † | 0.77 |
Severe | 9 (18.4) | 214 (11.1) | 8.02 (3.35 to 19.20)† | <0.001 | 1.18 (0.34 to 4.05) † | 0.79 |
Length of hospital stay, median (IQR) | 9.0 (4.0 to 19.0) | 10.0 (5.0 to 26.0) | 0.57 (0.33 to 0.98)‡ | 0.040 | 0.87 (0.41 to 1.84)‡ | 0.72 |
Death | 6 (12.2) | 119 (6.2) | 11.58 (4.10 to 32.69)† | <0.001 | 1.38 (0.30 to 6.20)† | 0.67 |
Values are presented as n (percentage) unless otherwise indicated. Values, effect size and p values were calculated after handle missing data by simple imputation.
*Effect size and p values calculated using propensity score overlap weighting analyses, using no MPA treatment group as reference.
†OR calculated using multinomial or binary logistic regression models.
‡Sub-HR (sHR) calculated among 645 hospitalised patients using Fine and Gray model with discharge alive as the event of interest and hospital death as the competing event. sHR >1 indicates an increase in length of hospital stay, and an sHR <1 indicates a decrease in length of hospital stay compared with the reference group.
MPA, mycophenolic acid; PSOW, propensity score overlap weighting.